http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2869339-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23e985a18173b95d89acbfff1cdb2ec0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 |
| filingDate | 2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62684a37fedf5437289e222b701ac7e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_518089010a96d4387fbdd3f68c4e1d5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72230441c96c9f64a652b10ebb16ebc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2abfed20cf7693af357ae53e5f7947d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f482f2cbe0c99abe9b92c22aa8b0df2d |
| publicationDate | 2021-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2869339-T3 |
| titleOfInvention | Truncated von Willebrand factor polypeptides for the treatment of hemophilia |
| abstract | A polypeptide comprising a truncated von Willebrand factor (VWF) and a half-life extending moiety, for use in treating a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and has endogenous factor VIII (FVIII), wherein the level of endogenous FVIII activity in said subject prior to treatment with said polypeptide is reduced relative to the level of FVIII activity in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the truncated VWF comprises an amino acid sequence that has at least 90% sequence identity to amino acids 764 to 1242 of SEQ ID NO:4, and wherein the polypeptide is capable of binding endogenous FVIII, wherein von Willebrand factor (VWF) tru ncado provides the ability of the polypeptide to bind endogenous FVIII; wherein the polypeptide is a dimer and the affinity of said dimer to FVIII is greater than the affinity of a monomeric polypeptide to said FVIII, said monomeric polypeptide having the same amino acid sequence as a monomeric subunit of the dimeric polypeptide; wherein the polypeptide has a binding affinity for FVIII characterized by a dissociation constant KD of less than 1 nM; wherein the half-life extending moiety is a heterologous amino acid sequence fused to the truncated VWF or conjugated to the polypeptide; and wherein the level of endogenous FVIII is increased after administration of said polypeptide and wherein - (i) said polypeptide is administered for prophylactic prevention of a bleeding event, wherein a) said treatment or not comprises co-administration of FVIII exogenous, or b) said treatment comprises administering an exogenous FVIII and thereby providing endogenous FVIII in said subject; or - (ii) said polypeptide is co-administered with exogenous FVIII for treatment of a bleeding event or for initiation of a prophylactic treatment regimen, wherein for follow-up treatments said polypeptide is co-administered without co-administration of exogenous FVIII. |
| priorityDate | 2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 288.